Get started
Author

Bianca A. M. H. van Veggel

Observed names: B. Van Veggel, B. van Veggel, B.A.M.H. van Veggel, B.V. Veggel, Bianca A M H van Veggel, Bianca A.M.H. van Veggel, Bianca Amh van Veggel, Bianca van Veggel, Veggel, B.A.M.H. van
ORCID: 0000-0002-3223-1255
Observed ORCID: 0000-0002-3223-1255
OpenAlex ID: A5006547437
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
2019 · B. van Veggel, J.F. Vilacha Madeira R Santos, et al. · Lung Cancer · 96
PDF
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
2022 · Fenneke Zwierenga, Bianca van Veggel, et al. · Lung Cancer · 67
PDF
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC
2018 · Bianca van Veggel, Adrianus J. de Langen, et al. · Journal of Thoracic Oncology · 64
PDF
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer
2019 · Sebastian Michels, Carina Heydt, et al. · JCO Precision Oncology · 36
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses
2018 · Bianca van Veggel, Adrianus J. de Langen, et al. · Lung Cancer · 24
Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy
2011 · Bianca A M H van Veggel, Inge M van Oort, et al. · Histopathology · 22
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
2022 · René J. Boosman, Merel Jebbink, et al. · Pharmaceutical Research · 21
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
2023 · Fenneke Zwierenga, Bianca A.M.H. van Veggel, et al. · Cancer Treatment Reviews · 17
PDF
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
2021 · Bianca van Veggel, Anthonie J. van der Wekken, et al. · Journal of Clinical Oncology · 10
P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
2018 · B. Van Veggel, A. Van Der Wekken, et al. · Journal of Thoracic Oncology · 9
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer
2023 · Bianca A. M. H. van Veggel, Anthonie J. van der Wekken, et al. · Cancer · 8
PDF
Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
2018 · B. van Veggel, A. van der Wekken, et al. · Annals of Oncology · 4
PDF
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment
2025 · Nikki de Rouw, Leila‐Sophie Otten, et al. · Clinical Pharmacology & Therapeutics · 3
PDF
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
2024 · F. Zwierenga, L. Zhang, et al. · Lung Cancer · 3
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
2025 · J.W.T. van der Wel, S.M. Ernst, et al. · Lung Cancer · 2
1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
2021 · F. Zwierenga, B.A.M.H. van Veggel, et al. · Annals of Oncology · 2
PDF
New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer
2019 · J. Fassunke, C. Heydt, et al. · Annals of Oncology · 1
1262P Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance
2024 · T. van der Wel, M. Jebbink, et al. · Annals of Oncology
A reply to “Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer”
2020 · Bianca van Veggel, Adrianus Johannes de Langen · Lung Cancer
Pharmacotherapy for treatment of lung cancer in the elderly
2015 · Bianca Amh van Veggel, Bonne Biesma, et al. · Expert Opinion on Pharmacotherapy
Works count: 21
Citation count: 389
H-index: 9
I10-index: 9
Year
Topic
Type